HRTS logo

HRTSTema Heart & Health ETF

$34.30
$0.0298
(0.09%)
Today
Updated: 04:00 PM EDT
Vol3,474.00
52W High$36.65
52W Low$27.24
News
all
press releases
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
News Placeholder
More News
News Placeholder
Why Did BCDA Stock Surge More Than 50% Today?
BioCardia said the U.S. Food and Drug Administration confirmed that its ongoing CardiAMP Heart Failure II study could support a premarket approval application for its cell therapy.
Stocktwits
News Placeholder
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Zacks
News Placeholder
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.
Stocktwits
News Placeholder
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.
Stocktwits
<
...
1
>

Advertisement|Remove ads.